Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study.

Competing Interests: Competing interests: GE received consultation honoraria from GSK outside the current work. LD received consultation honoraria from GSK outside the current work. DJ’s disclosures of commercial conflicts are as follows: AstraZeneca, Aurinia, BMS, Boehringer-Ingelheim, Chemocentryx, Chugai, CSL, GSK, Infla-RX, Janssen, Novartis, Roche/Genentech, Takeda and Vifor. LM received consultation honoraria from GSK outside the current work. PP received consultation honoraria from GSK, and Novartisand LEOPharma. Professor Camillo Ribi received consultation honoraria from GSK outside the current work. JS received Advisory Board fees from AstraZeneca and GSK. AV received consultation honoraria from GSK outside the current work. All other authors and collaborators declare no conflicts of interest.